Overview

Study Comparing Reduced Versus Standard Dose Post-transplantation Cyclophosphamide in Combination with Post-engraftment Anti-thymoglobin As Graft Versus Host Disease Prophylaxis in Alternative Donor Peripheral Stem Cell Transplantation

Status:
ACTIVE_NOT_RECRUITING

Trial end date:
2028-07-01

Target enrollment:

Participant gender:

Summary

This is a multi-center randomized study to compare the reduced-dose of post-transplantation cyclophosphamide (PTCY) at 35mg.kg to standard dose at 50mg/kg combined with tacrolimus and post-engraftment low dose anti-thymoglobin (ATG) as graft versus host disease (GVHD) prophylaxis in patients undergoing allogeneic stem cell transplantation from alternative donor.

Phase:

PHASE3

Details

Lead Sponsor:

Shanghai Jiao Tong University School of Medicine

Collaborator:

Shanghai Sixth People's Hospital, Shanghai Jiao Tong University School of Medicine